A Bayesian network meta-analysis of ALK inhibitor treatments in patients with ALK-positive non-small cell lung cancer.

Bei Zheng, Hong Jiang,Wenjuan Yang, Ying Li,Bingqing Liang,Jun Zhu, Nanmei Chen, Miao Chen,Meiling Zhang

Cancer medicine（2023）

Cited 1|Views5

No score

Abstract

Alectinib was the first choice for patients with ALK-positive NSCLC and even for those with BM, whereas lorlatinib was the second choice. Long-term follow-up and prospective studies are warranted to compare ALKis and to verify our conclusions directly.

Translated text

Key words

lung cancer,non‐small cell lung cancer,cell lung cancer,inhibitor treatments

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined